Clinical trials: Respiratory Disorder
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung…
- Trial name
- NCT03674827
- Testing
- PF-06936308
- Where
- 34 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Obstructive Sleep Apnea
Continuous Positive Airway Pressure (PAP) Titration and Treatment Versus Auto-adjusting PAP Treatment for Sleep Apnea
The purpose of this randomized prospective study is to compare the efficacy of two approaches to initiate Positive Airway Pressure (PAP) treatment in patients diagnosed as having obstructive sleep apnea (OSA) by portable…
- Trial name
- NCT00988351
- Testing
- Continuous positive airway pressure, Auto-adjusting positive airway pressure treatment
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- North Florida Foundation for Research and Education
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
- Trial name
- NCT05249829
- Testing
- mRNA-1273.529, mRNA-1273, mRNA-1273.214
- Where
- 29 sites in United Kingdom
- Volunteers
- 3,548 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Orthomyxoviridae Infection, Influenza
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Compared to young adults, the elderly mount a lower antibody response to vaccination. Thus, improvement of the immune response to influenza vaccination in this age group, which is at higher risk for influenza-related morbidity…
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00391053
- Testing
- High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
- Where
- 28 sites in United States
- Volunteers
- 3,851 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Asthma, Aspirin-induced
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
To diagnose aspirin hypersensitivity in asthmatics by using and safe, low-dose aspirin oral challenge. Hypothesis 1: A low dose of oral ASA (20 or 40 mg) will induce significantly different concentrations of arachidonic acid…
- Trial name
- ASAS (NCT01320072)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Montefiore Medical Center
Pulmonary Disease, Chronic Obstructive
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)
The primary objective of this Non Interventional Study is to measure changes in physical functioning, a surrogate for physical activity and exercise capacity, in COPD patients on treatment with Spiolto® Respimat® in routine daily…
- Trial name
- NCT02720757
- Testing
- Spiolto Respimat
- Where
- 6 sites in Belgium, Denmark and 4 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Pertussis, Pregnancy Related
Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women
This study evaluated the seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in…
- Trial name
- NCT03498300
- Testing
- Tdap vaccine
- Where
- Thailand
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Bronchopulmonary Dysplasia (BPD) is a multi-factorial disease process that is the end result of an immature, surfactant deficient lung that has been exposed to hyperoxia, mechanical ventilation and infection.
- Trial name
- NCT01941745
- Testing
- Half normal saline, Low Dose rhCC10, High dose rhCC10
- Where
- 3 sites in United States
- Volunteers
- 88 people
- Sponsor
- Tufts Medical Center
Sleep Apnea Syndromes, Sleep Initiation and Maintenance Disorders
Understanding the Sleep Apnea/Insomnia Interaction
Nearly half of all patients with obstructive sleep apnea have insomnia symptoms, and in some, but not all cases, these insomnia symptoms are caused by the obstructive sleep apnea.
- Trial name
- NCT01824472
- Testing
- CPAP, CBT, CC
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Pennsylvania
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer.
- Trial name
- NCT05242965
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Alpha1-antitrypsin Deficiency
Aralast alpha1-proteinase Inhibitor Surveillance Study
The primary objectives of this Phase 4, open label, prospective U.S. surveillance study are to evaluate the health outcomes of Alpha 1-Antitrypsin (AAT)-deficient subjects who are initiating treatment with ARALAST on…
- Trial name
- NCT00313144
- Testing
- ARALAST Alpha1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Baxalta now part of Shire
Healthy
AZD8848 Single Ascending Dose Study
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of AZD8848 in healthy subjects.
- Trial name
- NCT01560234
- Testing
- AZD8848
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with non-small cell lung cancer who have failed first-line chemotherapy for advanced disease.
- Trial name
- NCT00531934
- Testing
- Doxycline, erlotinib [Tarceva]
- Where
- 24 sites in France
- Volunteers
- 147 people
- Sponsor
- Hoffmann-La Roche
Acute Hypoxemic Respiratory Failure
Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if…
- Trial name
- KL4-AHRF-01 (NCT00578734)
- Testing
- Lucinactant
- Where
- 3 sites in United States, Chile
- Volunteers
- 165 people
- Sponsor
- Windtree Therapeutics
Covid19
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
A 2-part, multicenter, Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of upamostat in adult patients with COVID-19 disease who do not require inpatient care.
- Trial name
- NCT04723537
- Testing
- Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part B: Upamostat 200 or 400 mg
- Where
- 17 sites in United States, South Africa
- Volunteers
- 61 people
- Sponsor
- RedHill Biopharma Limited
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or…
- Trial name
- PEARLS (NCT02504372)
- Testing
- Pembrolizumab
- Volunteers
- 1,177 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
- Trial name
- STORM CHASER (NCT04625972)
- Testing
- AZD7442
- Where
- 57 sites in United States, United Kingdom
- Volunteers
- 1,131 people
- Sponsor
- AstraZeneca
Covid19
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
This is an interventional, multicenter, 2-arm, parallel-group, randomized, double-blind, placebo controlled, dose-escalation, safety and efficacy study of F-652 treatment versus placebo in patients aged 18 years or older with a…
- Trial name
- NCT04498377
- Testing
- F-652
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EVIVE Biotechnology
Swallowing Disorder, Respiratory Insufficiency
The Impact of High-Flow Nasal Cannula on Swallow Function
Background: High-flow nasal cannula (HFNC) is a non-invasive heated and humidified oxygen delivery device that is capable of delivering high-flow rates.
- Trial name
- NCT03590457
- Testing
- Airvo 2; High-Flow nasal cannula system
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.